Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

doi:10.5306/wjco.v10.i2.52

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12338)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1163

WORD

271

HTML

7350

Figures (1-2)

580

Tables (1-2)

190

Sum=9554

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

478

Download

564

Sum=1042

Publishing Process of This Article

Item

Count

Browse

859

Download

883

Sum=1742

Feb 24, 2019 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Feb 24, 2019; 10(2): 52-61
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.52

Full Size Figure Download Figure

Figure 1 Approved anti-vascular endothelial growth factor monoclonal antibodies in the treatment of metastatic colorectal cancer and their mechanisms of action. VEGF: Vascular endothelial growth factor; PIGF: Placental growth factor; FAK: Focal adhesion kinase; PI3K: Phosphoinositide 3-kinase; PLC-γ: Phospholipase C gamma; PKC: Protein kinase C; MAPK: Mitogen-activated protein kinases; Erk: Extracellular signal-regulated kinase.

Citation: Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol 2019; 10(2): 52-61
URL: https://www.wjgnet.com/2218-4333/full/v10/i2/52.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i2.52